{"id":"itcz-iv","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Elevated liver enzymes"},{"rate":null,"effect":"Renal impairment"},{"rate":null,"effect":"Infusion-related reactions"},{"rate":null,"effect":"Nausea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Itraconazole works by blocking a key enzyme in the fungal sterol synthesis pathway, leading to depletion of ergosterol and accumulation of toxic sterol precursors. This destabilizes the fungal cell membrane, causing cell death. The IV formulation allows systemic delivery for serious invasive fungal infections where oral bioavailability is inadequate.","oneSentence":"ITCZ-IV is an intravenous formulation of itraconazole, a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:17:24.170Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Invasive aspergillosis"},{"name":"Blastomycosis"},{"name":"Histoplasmosis"},{"name":"Cryptococcosis"}]},"trialDetails":[{"nctId":"NCT00784368","phase":"PHASE3","title":"A Pharmacokinetic Study of JK1211(Itraconazole [Itrizole]) Oral Solution in Participants With Deep Mycosis and Those With Febrile Neutropenia Suspected of Fungal Infection","status":"COMPLETED","sponsor":"Janssen Pharmaceutical K.K.","startDate":"2008-01","conditions":"Mycoses, Candidiasis, Aspergillosis","enrollment":55}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"ITCZ-IV","genericName":"ITCZ-IV","companyName":"Janssen Pharmaceutical K.K.","companyId":"janssen-pharmaceutical-k-k","modality":"Small molecule","firstApprovalDate":"","aiSummary":"ITCZ-IV is an intravenous formulation of itraconazole, a triazole antifungal that inhibits fungal cytochrome P450-dependent lanosterol 14α-demethylase, disrupting ergosterol synthesis in the fungal cell membrane. Used for Invasive aspergillosis, Blastomycosis, Histoplasmosis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}